For this proof of concept study, we used the anti-human mesothelin sdAb A1 previously validated by our group for SPECT imaging of triple-negative breast cancer and pancreatic ductal adenocarcinoma following radiolabeling with technetium-99 m (Montemagno et al. 2018, 1531). Here, MSLN is linked to triple-negative breast carcinoma.